Top

Annals of Nuclear Medicine

Published in:

01-06-2017 | Original Article

Long-term results and tolerability of tandem peptide receptor radionuclide therapy with ⁹⁰Y/¹⁷⁷Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study

Authors: Jolanta Kunikowska, Dariusz Pawlak, Marianna I. Bąk, Beata Kos-Kudła, Renata Mikołajczak, Leszek Królicki

Published in: Annals of Nuclear Medicine | Issue 5/2017

Abstract

Introduction

The peptide receptor radionuclide therapy (PRRT) with ⁹⁰Y and ¹⁷⁷Lu is a form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET).

Aim

The aim of the study was to evaluate clinical results and long-term side effects of tandem ⁹⁰Y /¹⁷⁷Lu-DOTATATE therapy in patients with NET. Additionally, we evaluated clinical results with reference to the primary site.

Materials and methods

59 patients with disseminated NET were included in the study prospectively. 3–5 cycles of combined 1:1 ⁹⁰Y/¹⁷⁷Lu-DOTATATE (total injected activity 11.1–16.65 GBq) with mixed amino acids for kidney protection were performed.

Results

During a median follow-up of 75.8 months, the PFS was 32.2 months, and the OS was 82 months; 25 patients died. Depending on primary tumor’s site, the PFS and the OS for pancreatic NET vs. small bowel, NET vs. large bowel, NET were 30.4 vs. 29.5 vs. 40.3 and 78.9 vs. 58.1 vs. 82.5, respectively. The observed 5-year overall survival was 63%, and a 2-year risk of progression was 39.4%. The following imaging response was observed: CR in 2%, PR in 22%, SD in 65%, and PD in 6% patients. The disease control rate was 89%. The objective response rate was 24%. The PRRT was well tolerated by all patients. One patient (2%) revealed MDS, and one patient (2%) grade 3 nephrotoxicity. No other grade 3 and 4 hematological or renal toxicity was observed.

Conclusions

These results indicated the tandem ⁹⁰Y/¹⁷⁷Lu-DOTATATE therapy for patients with disseminated/inoperable NET as highly effective and safe, considering long-term side effects. In the majority of patients, clinical improvement was observed.

Kwekkeboom D, Krenning EP, de Jong. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–13.PubMed

De Jong M, Bernard HF, Breeman WA, Bernard BF, Krenning EP. Combination of ⁹⁰Y- and ¹⁷⁷Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to ⁹⁰Y- or ¹⁷⁷Lu-labeled analogs only. J Nucl Med. 2002;43:123P–124P.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. J Nucl Med. 2005;46:13S–17S.PubMed

Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-ATATE and tandem ⁹⁰Y/¹⁷⁷Lu-ATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97.CrossRefPubMedPubMedCentral

Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9–15.CrossRefPubMed

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16. Erratum in: Eur J Nucl Med Mol Imaging. 2014; 41:584.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMed

Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152–6.PubMed

10.

Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-.A]-TOC versus [(90)Y-.A]-TOC plus [(177)Lu-.A]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100–6.CrossRefPubMed

11.

Dumont RA, Seiler D, Marincek N, Brunner P, Radojewski P, Rochlitz C, et al. Survival after somatostatin based radiopeptide therapy with (90)Y-.ATOC vs. (90)Y-.ATOC plus (177)Lu-.ATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging. 2014;5:46–55.PubMedPubMedCentral

12.

Horsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016;58:41–51.CrossRefPubMed

13.

Radojewski P, Dumont R, Marincek N, Brunner P, Mäcke HR, Müller-Brand J, et al. Towards tailored radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1231–7.CrossRefPubMed

14.

Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.CrossRefPubMed

15.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.CrossRefPubMed

16.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513. Erratum. N Engl J Med. 2011;364:1082.

17.

Yao JC, Shah MH, Ito T Bohas CL, Wolin EM, Van Cutsem E, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.CrossRefPubMedPubMedCentral

18.

Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol. 1987;14:343–53.PubMed

19.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–33.CrossRefPubMed

20.

Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-.ATOC and (177)Lu-.ATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93:189–96.CrossRefPubMed

21.

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [⁹⁰Y-.A]-D-Phe1-Tyr3-octreotide (⁹⁰Y-.ATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–5.CrossRefPubMed

22.

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with ⁹⁰Y-.ATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703–7.PubMed

23.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [⁹⁰Y-.A0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–56.CrossRefPubMed

24.

Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. ¹⁷⁷Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41:1845–51.CrossRefPubMed

25.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-.ATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43:518–25.CrossRefPubMed

26.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [⁹⁰Y-.A]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.CrossRefPubMed

27.

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRefPubMed

28.

Kwekkeboom DJ, de Herder WW, Kam BL, Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-.A⁰ ,Tyr³]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMed

29.

Kos-Kudła B, Blicharz-Dorniak J, Handkiewicz-Junak D Jarząb B, Jarząb M, Kunikowska J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013;64:418–43.CrossRefPubMed

Title: Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study
Authors: Jolanta Kunikowska
Dariusz Pawlak
Marianna I. Bąk
Beata Kos-Kudła
Renata Mikołajczak
Leszek Królicki
Publication date: 01-06-2017
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 5/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-017-1163-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-term results and tolerability of tandem peptide receptor radionuclide therapy with ⁹⁰Y/¹⁷⁷Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study

Abstract

Introduction

Aim

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Aim

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2017

Compared to 123I-MIBG SPECT/CT, 18F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma

Correlation between clinical symptoms and striatal DAT uptake in patients with DLB

Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT

Incidental spade-shaped FDG uptake in the left ventricular apex suggests apical hypertrophic cardiomyopathy

Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years

Glucose uptake of the muscle and adipose tissues in diabetes and obesity disease models: evaluation of insulin and β3-adrenergic receptor agonist effects by 18F-FDG